~~<i id='DDB798BFDB'><strike id='DDB798BFDB'><tt id='DDB798BFDB'><pre id='DDB798BFDB'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：hotspot 2025-09-29 06:22:03 Page View：7741

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Glen Campbell's doctor discusses his public struggle with Alzheimer's
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

Wikipedia

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Most antidepressants don't work on kids, teens, study finds

MattDtrich/TheIndianapolisStar/APThevastmajorityofantidepressantsgiventokidsandteensareineffectivean

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

With measles on the rise, a personal story of a devastating disease

AuthorEmmiHermanstandsbehindhersister,Marcie,whosurvivedmeaslesencephalitis,assheplaysthepiano.Court